Evidence map›Paper›PMID 29246172›Full record

ArticleOrphanet journal of rare diseases2017

Morphoproteomics and biomedical analytics coincide with clinical outcomes in supporting a constant but variable role for the mTOR pathway in the biology of congenital hyperinsulinism of infancy.

Robert E Brown, Senthil Senniappan, Khalid Hussain, Mary F McGuire

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Robert E BrownDepartment of Pathology and Laboratory Medicine, UT Health McGovern Medical School, Houston, TX, USA. robert.brown@uth.tmc.edu.
Senthil SenniappanDepartment of Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, L12 2AP, UK.
Khalid HussainDepartment of Paediatric Medicine Division of Endocrinology, Sidra Medical & Research Center OPC, C6-337, PO Box 26999, Doha, Qatar.
Mary F McGuireBiomedical Analytics, Houston, TX, USA.
Alder Hey Children's Hospital · GBSidra Medical and Research Center · QAThe University of Texas Health Science Center at Houston · US

Funding

Medical Research Council MR/M023265/1
6 · The paper itself

Abstract

We first introduced the concept of the mTOR pathway's involvement in congenital hyperinsulinism of infancy (CHI), based largely on morphoproteomic observations and clinical outcomes using sirolimus (rapamycin) as a therapeutic agent in infants refractory to octreotide and diazoxide treatment. Subsequent publications have verified the efficacy of such treatment in some cases but limited and variable in others. We present further evidence of a constant but variable role for the mTOR pathway in the biology of CHI and provide a strategy that allows for the short-term testing of sirolimus in individual CHI patients.

Indexed as

Congenital HyperinsulinismDiazoxideHumansInfantOctreotideProteomicsSignal TransductionSirolimusTOR Serine-Threonine KinasesDiazoxideMTOR protein, humanOctreotideSirolimusTOR Serine-Threonine KinasesBiomedical analyticsCongenital hyperinsulinism of infancyMorphoproteomicsSirolimus

Identifiers

PMID29246172
PMCPMC5732475
OpenAlexW2774579657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.